Safety of Therapeutic Step-down in Neuromyelitis Optica

计划入组 947 人 · 首次发布于 2021 年 12 月 13 日

Neuromyelitis Optica (NMO) & Cetirizine

计划入组 16 人 · 首次发布于 2016 年 8 月 12 日

Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica

计划入组 3 人 · 首次发布于 2011 年 4 月 20 日

AIM Biological (neuromyelitis optica/parkinson's disease)

Satralizumab(Enspryng)

Rx

Inebilizumab(Uplizna 3 Vial Kit, Uplizna)

Rx

Optiva Inc

Australia

CW OPTICS, INC.

United States

Hoya Surgical Optics, Inc.

United States

Bio-Thera's BAT4406F Shows Promise in Neuromyelitis Optica Spectrum Disorders

FDA Blocks Approval of AstraZeneca's Ultomiris for Neuromyelitis Optica Spectrum Disorder

Bio-Thera's BAT4406F Achieves Early Trial Success in Rare Neurological Disorder NMOSD